Improving colorectal cancer management: The potential of proteomics

Biomarkers in Medicine

Volumn 2, Issue 3, 2008, Pages 253-289

  Derijks Engwegen, Judith Y M N ^a,b   Cats, Annemieke ^c   Smits, Marianne E ^c   Schellens, Jan H M ^d,e   Beijnen, Jos H ^a,e  

^a Sittard Geleen Heerlen   (Netherlands)

^b SLOTERVAART HOSPITAL   (Netherlands)

^c NETHERLANDS CANCER INSTITUTE   (Netherlands)

^d ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^e UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Biomarkers; Colorectal cancer; Proteomics

Indexed keywords

7 HYDROXYSTAUROSPORINE; ANTINEOPLASTIC AGENT; APOPTOTIC PROTEASE ACTIVATING FACTOR 1; AUTOANTIBODY; BIOLOGICAL MARKER; BORTEZOMIB; BRYOSTATIN; CALVASCULIN; CATHEPSIN D; CYTOKERATIN 19; CYTOKERATIN 20; DOXORUBICIN; FASCIN; FLUOROURACIL; GEMCITABINE; HEAT SHOCK PROTEIN 60; IRINOTECAN; PROTEIN TYROSINE KINASE INHIBITOR; THIOREDOXIN; THIOREDOXIN INHIBITOR; VIMENTIN;

ADVANCED CANCER; ANTIBODY SCREENING; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CLINICAL TRIAL; COLONOSCOPY; COLORECTAL CANCER; DRUG MECHANISM; DRUG TARGETING; EARLY DIAGNOSIS; FECES ANALYSIS; FOLLOW UP; GENE EXPRESSION PROFILING; HUMAN; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; NONHUMAN; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEOMICS; REVIEW; SENSITIVITY AND SPECIFICITY; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; TWO DIMENSIONAL GEL ELECTROPHORESIS;

EID: 48349135781     PISSN: 17520363     EISSN: None     Source Type: Journal    
DOI: 10.2217/17520363.2.3.253     Document Type: Review

References (169)

1. Weitz J, Koch M, Debus J, Hohler T, Galle PR, Buchler MW: Colorectal cancer. Lancet 365(9454), 153-165 (2005).
2. Vogelstein B, Kinzler KW: The multistep nature of cancer. Trends Genet. 9(4), 138-141 (1993).
3. Walsh JM, Terdiman JP: Colorectal cancer screening: scientific review. JAMA 289(10), 1288-1296 (2003).
4. Ramsoekh D, van Leerdam ME, van Ballegooijen M, Habbema JD, Kuipers EJ: Population screening for colorectal cancer: feces, endoscopes or X-rays? Cell Oncol. 29(3), 185-194 (2007).
5. Ouyang DL, Chen JJ, Getzenberg RH, Schoen RE: Noninvasive testing for colorectal cancer: a review. Am. J. Gastroenterol. 100(6), 1393-1403 (2005).
6. Imperiale TF, Ransohoff DF, Itzkowitz SH, Turnbull BA, Ross ME: The Colorectal Cancer Study Group: fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population. N. Engl. J. Med. 351(26), 2704-2714 (2004).
7. Duffy MJ: Carcinoembryonic antigen as a marker for colorectal cancer: is it clinically useful? Clin. Chem. 47(4), 624-630 (2001).
8. Ahlquist DA, Wieand HS, Moertel CG et al.: Accuracy of fecal occult blood screening for colorectal neoplasia. A prospective study using Hemoccult and HemoQuant tests. JAMA 269(10), 1262-1267 (1993).
9. Greenberg PD, Bertario L, Gnauck R et al.: A prospective multicenter evaluation of new fecal occult blood tests in patients undergoing colonoscopy. Am. J. Gastroenterol. 95(5), 1331-1338 (2000).
10. Duffy MJ, van Dalen A, Haglund C et al.: Clinical utility of biochemical markers in colorectal cancer: European Group on Tumor Markers (EGTM) guidelines. Eur. J. Cancer 39(6), 718-727 (2003).
11. Locker GY, Hamilton S, Harris J et al.: ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J. Clin. Oncol. 24(33), 5313-5327 (2006).
12. Ahmed FE: Molecular markers that predict response to colon cancer therapy. Expert Rev. Mol. Diagn. 5(3), 353-375 (2005).
13. Mader RM: Links between biology, prognosis and prediction of response to chemotherapy in colorectal cancer. Onkologie 29 (7), 334-341 (2006).
14. Engwegen JYMN, Gast MCW, Schellens JHM, Beijnen JH: Clinical proteomics: searching for better tumor markers with SELDI-TOF mass spectrometry. Trends Pharmacol. Sci. 27(5), 251-259 (2006).
15. Sagynaliev E, Steinert R, Nestler G, Lippert H, Knoch M, Reymond MA: Web-based data warehouse on gene expression in human colorectal cancer. Proteomics 5(12), 3066-3078 (2005).
16. Lilley KS, Razzaq A, Dupree P: Two-dimensional gel electrophoresis: recent advances in sample preparation, detection and quantitation. Curr. Opin. Chem. Biol. 6(l), 46-50 (2002).
17. Binz PA, Hochstrasser DF, Appel RD: Mass spectrometry-based proteomics: current status and potential use in clinical chemistry. Clin. Chem. Lab Med. 41(12), 1540-1551 (2003).
18. Ott V, Guenther K, Steinert R et al.: Accuracy of two-dimensional electrophoresis for target discovery in human colorectal cancer. Pharmacogenomics J. 1(2), 142-151 (2001).
19. Mazzanti R, Solazzo M, Fantappie O et al.: Differential expression proteomics of human colon cancer. Am. J. Physiol Gastrointest. Liver Physiol 290(6), G1329-G1338 (2006).
20. Bi X, Lin Q, Foo TW et al.: Proteomic analysis of colorectal cancer reveals alterations in metabolic pathways: mechanism of tumorigenesis. Mol. Cell Proteomics 5(6), 1119-1130 (2006).
21. Lawrie LC, Dundas SR, Curran S, Murray GI: Liver fatty acid binding protein expression in colorectal neoplasia. Br. J. Cancer 90(10), 1955-1960 (2004).
22. Polley AC,, Mulholland F, Pin C et al.: Proteomic analysis reveals field-wide changes in protein expression in the morphologically normal mucasa of patients with colorectal neoplasia. Cancer Res. 66(13), 6553-6562 (2006).
23. Fillet M, Cren-Olive C, Renert AF et al.: Differential expression of proteins in response to ceramide-mediated stress signal in colon cancer cells by 2D gel electrophoresis and MALDI-TOF-MS. J. Proteome. Res 4(3), 870-880 (2005).
24. Shitashige M, Naishiro Y, Idogawa M et al.: Involvement of splicing factor-1 in β-catenin/T-cell factor-4-mediated gene transactivation and pre-mRNA splicing. Gastroenterology 132(3), 1039-1054 (2007).
25. Rahman-Roblick R, Roblick UJ, Hellman U et al.: p53 targets identified by protein expression profiling. Proc. Natl Acad. Sci. USA 104(13), 5401-5406 (2007).
26. Drew JE, Rucklidge GJ, Duncan G et al.: A proteomics approach to identify changes in protein profiles in pre-cancerous colon. Biochem. Biophys. Res. Commun. 330(1), 81-87 (2005).
27. Cole AR, Ji H, Simpson RJ: Proteomic analysis of colonic crypts from normal, multiple intestinal neoplasia and p53-null mice: a comparison with colonic polyps. Electrophoresis 21(9), 1772-1781 (2000).
28. Zhao L, Liu L, Wang S, Zhang YF, Yu L, Ding YQ: Differential proteomic analysis of human colorectal carcinoma cell lines metastasis-associated proteins. J. Cancer Res. Clin. Oncol. 133(10), 771-782 (2007).
29. Ahmed N, Oliva K, Wang Y, Quinn M, Rice G: Proteomic profiling of proteins associated with urokinase plasminogen activator receptor in a colon cancer cell line using an antisense approach. Proteomics 3(3), 288-298 (2003).
30. Katayama M, Nakano H, Ishiuchi A et al.: Protein pattern difference in the colon cancer cell lines examined by two-dimensional differential in-gel electrophoresis and mass spectrometry Surg. Today 36(12), 1085-1093 (2006).
31. Yoo BC, Jeon E, Hong SH, Shin YK, Chang HJ, Park JG: Metabotropic glutamate receptor 4-mediated 5-fluorouracil resistance in a human colon cancer cell line. Clin. Cancer Res. 10 (12), 4176-4184 (2004).
32. Skvortsov S, Sarg B, Loeffler-Ragg J et al.: Different proteome pattern of epidermal growth factor receptor-positive colorectal cancer cell lines that are responsive and nonresponsive to C225 antibody treatment. Mol. Cancer Ther. 3(12), 1551-1558 (2004).
33. Loeffler-Ragg J, Skvortsov S, Sarg B et al.: Gefitinib-responsive EGFR-positive colorectal cancers have different proteome profiles from non-responsive cell lines. Eur. J. Cancer 41(15), 2338-2346 (2005).
34. Tan S, Seow TK, Liang RC et al.: Proteome analysis of butyrate-treated human colon cancer cells (HT-29). Int. J. Cancer 98(4), 523-531 (2002).
35. Tan HT, Zubaidah RM, Tan S, Hooi SC, Chung MC: 2D DIGE analysis of butyrate-treated HCT-116 cells after enrichment with heparin affinity chromatography. J. Proteome. Res. 5(5), 1098-1106 (2006).
36. Lou J, Fatima N, Xiao Z et al.: Proteomic profiling identifies cyclooxygenase-2-independent global proteomic changes by celecoxib in colorectal cancer cells. Cancer Epidemiol. Biomarkers Prev. 15(9), 1598-1606 (2006).
37. Wang YJ, Zhang GY, Xiao ZQ, Wang HM, Chen ZC: Preliminary proteomic analysis of indomethacin's effect on tumor transplanted with colorectal cancer cell in nude mice. J. Biochem. Mol. Biol. 39(2), 171-177 (2006).
38. Lensaerts K, Bouwman FG, Lamers WH, Renes J, Mariman EC: Comparative proteomic analysis of cell lines and scrapings of the human intestinal epithelium. BMC Genomics 8, 91 (2007).
39. Li JQ, Xu BJ, Shakhtour B et al.: Variability of in situ proteomic profiling and implications for study design in colorectal tumors. Int. J. Oncol. 31(1), 103-111 (2007).
40. Kwong KY, Bloom GC, Yang I et al.: Synchronous global assessment of gene and protein expression in colorectal cancer progression. Genomics 86(2), 142-158 (2005).
41. Roblick UJ, Hirschberg D, Habermann JK et al.: Sequential proteome alterations during genesis and progression of colon cancer. Cell. Mol. Life Sci. 61(10), 1246-1255 (2004).
42. Stulik J, Koupilova K, Osterreicher J et al.: Protein abundance alterations in matched sets of macroscopically normal colon mucosa and colorectal carcinoma. Electrophoresis 20(18), 3638-3646 (1999).
43. Melis R, White R: Characterization of colonic polyps by two-dimensional gel electrophoresis. Electrophoresis 20(4-5), 1055-1064 (1999).
44. Stulik J, Hernychova L, Porkertova S et al.: Proteome study of colorectal carcinogenesis. Electropboresis 22(14), 3019-3025 (2001).
45. Habermann JK, Paulsen U, Roblick UJ et al.: Stage-specific alterations of the genome, transcriptome, and proteome during colorectal carcinogenesis. Genes Chromosomes Cancer 46(1), 10-26 (2007).
46. Banks RE, Dunn MJ, Forbes MA et al.: The potential use of laser capture microdissection to selectively obtain distinct populations of cells for proteomic analysis: preliminary findings. Electrophoresis 20(4-5), 689-700 (1999).
47. Bonner RF, Emmert-Buck M, Cole K et al.: Cell sampling: laser capture microdissection: molecular analysis of tissue. Science 278(5342), 1481-1483 (1997).
48. Melle C, Osterloh D, Ernst G, Schimmel B, Bleul A, Von Eggeling F: Identification of proteins from colorectal cancer tissue by two-dimensional gel electrophoresis and SELDI mass spectrometry. Int. J. Mol. Med. 16(1), 11-17 (2005).
49. Lawrie LC, Curran S, McLeod HL, Fothergill JE, Murray GI: Application of laser capture microdissection and proteomics in colon cancer. Mol. Pathol. 54(4), 253-258 (2001).
50. Madoz-Gúrpide J, Lopez-Serra P, Martinez-Torrecuadrada JL, Sanchez L, Lombardia L, Casal JI: Proteomics-based validation of genomic data: applications in colorectal cancer diagnosis. Mol. Cell Proteomics 5(8), 1471-1483 (2006).
51. Mueller MM, Fusenig NE: Friends or foes: bipolar effects of the tumor stroma in cancer. Nat. Rev. Cancer 4(11), 839-849 (2004).
52. Krieg RC, Fogt F, Braunschweig T, Herrmann PC, Wolischeidt V, Wellmann A: ProteinChip array analysis of microdissected colorectal carcinoma and associated tumor stroma shows specific protein bands in the 3,4 to 3,6 kDa range. Anticancer Res. 24(3a), 1791-1796 (2004).
53. Stoeckli M, Chaurand P, Hallahan DE, Caprioli RM: Imaging mass spectrometry: a new technology for the analysis of protein expression in mammalian tissues. Nat. Med. 7(4), 493-496 (2001).
54. Rodriguez-Pineiro AM, Ayude D, Rodriguez-Berrocal FJ, Paez DLC: Concanavalin A chromatography coupled to two-dimensional gel electrophoresis improves protein expression studies of the serum proteome. J. Chromatogr B Analyt. Technol. Biomed. Life Sci. 803(2), 337-343 (2004).
55. Roessler M, Rollinger W, Mantovani-Endl L et al.: Identification of PSME3 as a novel serum tumor marker for colorectal cancer by combining two-dimensional polyacrylamide gel electrophoresis with a strictly mass spectrometry-based approach for data analysis. Mol. Cell. Proteomics 5(11), 2092-2101 (2006).
56. Roessier M, Rollinger W, Palme S et al.: Identification of nicotinamide N-methyltransferase as a novel serum tumor marker for colorectal cancer. Clin. Cancer Res. 11(18), 6550-6557 (2005).
57. Melle C, Ernst G, Schimmel B et al.: Discovery and identification of α-defensins as low abundant, tumor-derived serum markers in colorectal cancer. Gastroenteroly 129(1), 66-73 (2005).
58. Albrethsen J, Bogebo R, Gammeltoft S, Olsen J, Whither B, Raskov H: Upregulated expression of human neutrophil peptides 1, 2 and 3 (HNP 1-3) in colon cancer serum and tumors: a biomarker study. BMC Cancer 5(1), 8 (2005).
59. Albrethsen J, Moller CH, Olsen J, Raskov H, Gammeltoft S: Human neutrophil peptides 1, 2 and 3 are biochemical markers for metastatic colorectal cancer. Eur. J. Cancer 42(17), 3057-3064 (2006).
60. Chen Yd, Zheng S, Yu Jk, Hu X: Artificial neural networks analysis of surface-enhanced laser desorption/ionization mass spectra of serum protein pattern distinguishes colorectal cancer from healthy population. Clin. Cancer Res. 10(24), 8380-8385 (2004).
61. Liu XP, Shen J, Li ZF, Yan L, Gu J: A serum proteomic pattern for the detection of colorectal adenocarcinoma using surface enhanced laser desorption and ionization mass spectrometry. Cancer Invest. 24(8), 747-753 (2006).
62. De Noo ME, Mertens BJ, Ozalp A et al.: Detection of colorectal cancer using MALDI-TOF serum protein profiling. Eur. J. Cancer 42(8), 1068-1076 (2006).
63. Ragazzi E, Pucciarelli S, Seraglia R et al.: Multivariate analysis approach to the plasma protein profile of patients with advanced colorectal cancer. J. Mass Spectrom. 41(12), 1546-1553 (2006).
64. Ward DG, Suggett N, Cheng Y et al.: Identification of serum biomarkers for colon cancer by proteomic analysis. Br. J. Cancer 94(12), 1898-1905 (2006).
65. Habermann JK, Roblick UJ, Luke BT et al.: Increased serum levels of complement C3a anaphylatoxin indicate the presence of colorectal tumors. Gastroenterology 131(4), 1020-1029 (2006).
66. Engwegen JYMN, Helgason HH, Cats A et al.: Identification of serum proteins discriminating colorectal cancer patients and healthy controls using surface-enhanced laser desorption ionisation-time of flight mass spectrometry. World J. Gastroenterol. 12(10), 1536-1544 (2006).
67. Engwegen JYMN, Alberts M, Knol JC et al.: Influence of variations in sample handling on SELDI-TOF MS serum protein profiles for colorectal cancer. Proteomics Clin. Appl. (2008) (In Press).
68. Villanueva J, Shaffer DR, Philip J et al.: Differential exoprotease activities confer tumor-specific serum peptidome patterns. J. Clin. Invest. 116(l), 271-284 (2006).
69. Smith FM, Gallagher. WM, Fox E et al.: Combination of SELDI-TOF MS and data mining provides early-stage response prediction for rectal tumors undergoing multimodal neoadjuvant therapy. Ann. Surg. 245(2), 259-266 (2007).
70. Helgason HH, Engwegen JYMN, Cats A et al.: Effect of oxaliplatin-capecitabine firsline chemotherapy and tumor response on serum proteomic profiles in advanced colorectal cancer and identification of diagnostic biomarkers. J. Clin. Oncol. 24(18S), 3603 (2006).
71. Caron M, Choquet-Kastylevsky G, Joubert-Caron R: Cancer immunomics using autoantibody signatures for biomarker discovery. Mol. Cell. Proteomics 6(7), 1115-1122 (2007).
72. Le Naour F, Brichory F, Beretta L, Hanash SM: Identification of tumor-associated antigens using proteomics. Technol. Cancer Res. Treat. 1(4), 257-262 (2002).
73. Scanlan MJ, Chen YT, Williamson B et al.: Characterization of human colon cancer antigens recognized by autologous antibodies. Int. J. Cancer 76(5), 652-658 (1998).
74. Nam MJ, Madoz-Gurpide J, Wang H et al.: Molecular profiling of the immune response in colon cancer using protein microarrays: occurrence of autoantibodies to ubiquitin C-terminal hydrolase L3. Proteomics 3(l1), 2108-2115 (2003).
75. Lu H, Goodell V, Disis ML: Targeting serum antibody for cancer diagnosis: a focus on colorectal cancer. Expert Opin. Ther. Targets. 11(2), 235-244 (2007).
76. Dubrow R, Yannielli L: Fecal protein markers of colorectal cancer. Am. J. Gastroenterol. 87(7), 854-858 (1992).
77. Moran A, Hendrickse C, Jones AF, Neoptolemos I Enteric α-1-antitrypsin loss and comparison with Okokit II and Haemoccult for the detection of colorectal cancer. Surg. Oncol.3(3), 147-151 (1994).
78. Yokoyama S, Shatney CH, Mochizuki H et al.: The potential role of fecal carbonic anhydrase II in screening for colorectal cancer. Am. Surg. 63(3), 243-246 (1997).
79. Tonus C, Neupert G, Sellinger M: Colorectal cancer screening by non-invasive metabolic biomarker fecal tumor M2-PK. World J. Gastroenterol. 12(43), 7007-7011 (2006).
80. Shastri YM, Naumann M, Oremek GM et al.: Prospective multicenter evaluation of fecal tumor pyruvate kinase type M2 (M2-PK) as a screening biomarker for colorectal neoplasia. Int. J. Cancer 119(11), 2651-2656 (2006).
81. Kumar Y, Tapuria N, Kirmani N, Davidson BR: Tumor M2-pyruvate kinase: a gastrointestinal cancer marker. Eur. J. Gastroenterol. Hepatol. 19(3), 265-276 (2007):
82. Alaiya AA, Roblick UJ, Franzen B, Bruch HP, Auer G: Protein expression profiling in human lung, breast, bladder, renal, colorectal and ovarian cancers. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 787(1), 207-222 (2003).
83. Cho WC: Contribution of oncoproteomics to cancer biomarker discovery. Mol. Cancer 6(25) (2007).
84. Mendes KN, Nicorici D, Cogdell D et al.: Analysis of signaling pathways in 90 cancer cell lines by protein lysate array. J. Proteome Res. 6(7), 2753-2767 (2007).
85. Roesch-Ely M, Nees M, Karsai S et al.: Proteomic analysis reveals successive aberrations in protein expression from healthy mucosa to invasive head and neck cancer. Oncogene 26(1), 54-64 (2007).
86. Isomoto H, Mukae H, Ishimoto H et al.: Elevated concentrations of α-defensins in gastric juice of patients with Helicobacter pylori infection. Am. J. Gastroenterol. 99(10), 1916-1923 (2004).
87. Fung ET, Yip TT, Lomas L et al.: Classification of cancer types by measuring variants of host response proteins using SELDI serum assays. Int. J. Cancer 115(5), 783-789 (2005).
88. Sis B, Sagol O, Kupelioglu A et al.: Prognostic significance of matrix metalloproteinase-2, cathepsin D, and tenascin-C expression in colorectal carcinoma. Pathol. Res. Pract. 200(5), 379-387 (2004).
89. Oh-e H, Tanaka S, Kitadai Y, Shimamoto F, Yoshihara M, Haruma K: Cathepsin D expression as a possible predictor of lymph node metastasis in submucosal colorectal cancer. Eur. J. Cancer 37(2), 180-188 (2001).
90. Gongoll S, Peters G, Mengel M et al.: Prognostic significance of calcium-binding protein S100A4 in colorectal cancer. Gastroenterology 123(5), 1478-1484 (2002).
91. Flatmark K, Pedersen KB, Nesland JM et al.: Nuclear localization of the metastasis-related protein S100A4 correlates with tumor stage in colorectal cancer. J. Pathol. 200(5), 589-595 (2003).
92. Hemandas AK, Salto-Tellez M, Maricar SH, Leong AF, Leow CK: Metastasis-associated protein S100A4: a potential prognostic marker for colorectal cancer. J. Surg. Oncol. 93(6), 498-503 (2006).
93. Flatmark K, Maelandsmo GM, Mikalsen SO et al.: Immunofluorometric assay for the metastasis-related protein S100A4: release of S100A4 from normal blood cells prohibits the use of S100A4 as a tumor marker in plasma and serum. Tumor. Biol. 25(1-2), 31-40 (2004).
94. Zlobec I, Minoo P, Baker K et al.: Loss of APAF-1 expression is associated with tumor progression and adverse prognosis in colorectal cancer. Eur. J. Cancer 43(6), 1101-1107 (2007).
95. Zlobec I, Lugli A, Baker K et al.: Role of APAF-1, E-cadherin and peritumoral lymphocytic infiltration in tumor budding in colorectal cancer. J. Pathol. 212(3), 260-268 (2007).
96. Koukourakis MI, Giatromanolaki A, Sivridis E, Gatter KC, Harris AL: Lactate dehydrogenase 5 expression in operable colorectal cancer: strong association with survival and activated vascular endothelial growth factor pathway: a report of the Tumor Angiogenesis Research Group. J. Clin. Oncol. 24(26), 4301-4308 (2006).
97. Hashimoto Y, Skacel M, Lavery IC, Mukherjee AL, Casey G, Adams JC: Prognostic significance of fascin expression in advanced colorectal cancer: an immunohistochemical study of colorectal adenomas and adenocarcinomas. BMC Cancer 6, 241 (2006).
98. Tsai WC, Chao YC, Sheu LF, Chang IL, Nieh S, Jin JS: Overexpression of fascin-1 in advanced colorectal adenocarcinoma: tissue microarray analysis of immunostaining scores with clinicopathological parameters. Dis. Markers 23(3), 153-160 (2007).
99. Dundas SR, Lawrie LC, Rooney PH, Murray GI: Mortalin is over-expressed by colorectal adenocarcinomas and correlates with poor survival. J. Pathol. 205(1), 74-81 (2005).
100. Boltze C: Loss of maspin is a helpful prognosticator in colorectal cancer: a tissue microarray analysis. Pathol. Res. Pract. 200(11-12), 783-790 (2005).
101. Dietmaier W, Bettstetter M, Wild PJ et al.: Nuclear maspin expression is associated with response to adjuvant 5-fluorouracil based chemotherapy in patients with stage III colon cancer. Int. J. Cancer 118(9), 2247-2254 (2006).
102. Carpenter B, McKay M, Dundas SR, Lawrie LC, Telfer C, Murray GI: Heterogeneous nuclear ribonucleoprotein K is over expressed, aberrantly localised and is associated with poor prognosis in colorectal cancer. Br. J. Cancer 95(7), 921-927 (2006).
103. Silva JM, Rodriguez R, Garcia JM et al.: Detection of epithelial tumor RNA in the plasma of colon cancer patients is associated with advanced stages and circulating tumor cells. Gut 50(4), 530-534 (2002).
104. Wang JY, Lin SR, Wu DC et al.: Multiple molecular markers as predictors of colorectal cancer in patients with normal perioperative serum carcinoembryonic antigen levels. Clin. Cancer Res. 13(8), 2406-2413 (2007).
105. Khair G, Monson JR, Greenman J: Epithelial molecular markers in the peripheral blood of patients with colorectal cancer. Dis. Colon Rectum 50 (8), 1188-1203 (2007).
106. Merrie AE, van Rij AM, Dennett ER, Phillips LV, Yun K, McCall JL: Prognostic significance of occult metastases in colon cancer. Dis. Colon Rectum 46(2), 221-231 (2003).
107. Miyake Y, Yamamoto H, Fujiwara Y et al.: Extensive micrometastases to lymph nodes as a marker for rapid recurrence of colorectal cancer: a study of lymphatic mapping. Clin. Cancer Res. 7(5), 1350-1357 (2001).
108. Lassmann S, Bauer M, Rosenberg R et al.: Identification of occult tumor cells in node negative lymph nodes of colorectal cancer patients by cytokeratin-20 gene and protein expression. Int. J. Colorectal Dis. 19(2), 87-94 (2004).
109. Rosenberg R, Hoos A, Mueller J et al.: Prognostic significance of cytokeratin-20 reverse transcriptase polymerase chain reaction in lymph nodes of node-negative colorectal cancer patients. J. Clin. Oncol. 20(4), 1049-1055 (2002).
110. Ikeda S, Fujimori M, Shibata S et al.: Combined immunohistochemistry of β-catenin, cytokeratin 7, and cytokeratin-20 is useful in discriminating primary lung adenocarcinomas from metastatic colorectal cancer. BMC Cancer 6, 31 (2006).
111. Tsao SC, Su YC, Wang SL, Chai CY: Use of caveolin- 1, thyroid transcription factor- 1, and cytokeratins-7 and -20 in discriminating between primary and secondary pulmonary adenocarcinoma from breast or colonic origin. Kaohsiung J. Med. Sci. 23(7), 325-331 (2007).
112. Hernandez BY, Frierson HF, Moskaluk CA et al.: CK20 and CK7 protein expression in colorectal cancer: demonstration of the utility of a population-based tissue microarray. Hum. Pathol. 36(3), 275-281 (2005).
113. Zhang PJ, Shah M, Spiegel GW, Brooks JJ: Cytokeratin-7 immunoreactivity in rectal adenocarcinomas. Appl. Immunohistochem. Mol. Morphol. 11(4), 306-310 (2003).
114. Tatsumi N, Mukaisho K, Mitsufuji S et al.: Expression of cytokeratins-7 and -20 in serrated adenoma and related diseases. Dig. Dis.Sci. 50(9), 1741-1746 (2005).
115. Soussi T: p53 Antibodies in the sera of patients with various types of cancer: a review. Cancer Res. 60(7), 1777-1788 (2000).
116. Tang R, Ko MC, Wang JY et al.: Humoral response to p53 in human colorectal tumors: a prospective study of 1,209 patients. Int. J. Cancer 94(6), 859-863 (2001).
117. Lechpammer M, Lukac J, Lechpammer S, Kovacevic D, Loda M, Kusic Z: Humoral immune response to p53 correlates with clinical course in colorectal cancer patients during adjuvant chemotherapy. Int. J. Colorectal Dis. 19(2), 114-120 (2004).
118. Watanabe T, Komuro Y, Kiyomatsu T et al.: Prediction of sensitivity of rectal cancer cells in response to preoperative radiotherapy by DNA microarray analysis of gene expression profiles. Cancer Res. 66(7), 3370-3374 (2006).
119. Tampellini M, Saini A, Alabiso I et al.: The role of hemoglobin level in predicting the response to first-line chemotherapy in advanced colorectal cancer patients. Br. J. Cancer 95(1), 13-20 (2006).
120. Hecht JR, Trarbach T, Jaeger E et al.: A randomized, double-blind, placebo-controlled, Phase III study in patients with metastatic adenocarcinoma of the colon or rectum receiving first-line chemotherapy with oxaliplatin/5-fluorouracil/leucovorin and PTK787/ZK 222584 or placebo (CONFIRM-1). Proc. Am. Soc. Clin. Oncol. 23(16S), 3 (2005).
121. Koehne C, Bajetta E, Lin E et al.: Results of an interim analysis of a multinational randomized, double-blind, Phase III study in patients with previously treated metastatic colorectal cancer (mCRC) receiving FOLFOX4 and PTK787/ZK 222584 (PTK/ZK) or placebo (CONFIRM-2). Proc. Am. Soc. Clin. Oncol. 24(18S), 3508 (2006).
122. Wiedmann MW, Caca K: Molecularly targeted therapy for gastrointestinal cancer. Curr. Cancer Drug Targets 5(3), 171-193 (2005).
123. Ryan DP, O'Neil BH, Supko JG et al.: A Phase I study of bortezomib plus irinotecan in patients with advanced solid tumors. Cancer 107(11), 2688-2697 (2006).
124. Mackay H, Hedley D, Major P et al.: A Phase II trial with pharmacodynamic endpoints of the proteasome inhibitor bortezomib in patients with metastatic colorectal cancer. Clin. Cancer Res. 11(15), 5526-5533(2006).
125. Zonder JA, Shields AF, Zalupski M et al.: A Phase II trial of bryostatin 1 in the treatment of metastatic colorectal cancer. Clin. Cancer Res. 7(1), 38-42 (2001).
126. Edelman MJ, Bauer KS Jr, Wu S, Smith R, Bisacia S, Dancey J: Phase I and pharmacokinetic study of 7-hydroxystaurosporine and carboplatin in advanced solid tumors. Clin. Cancer Res. 13(9), 2667-2674 (2007).
127. Hotte SJ, Oza A, Winquist EW et al.: Phase I trial of UCN-01 in combination with topotecan in patients with advanced solid cancers: a Princess Margaret Hospital Phase II Consortium study. Ann. Oncol. 17(2), 334-340 (2006).
128. Dees EC, Baker SD, O'Reilly S et al.: A Phase I and pharmacokinetic study of short infusions of UCN-01 in patients with refractory solid tumors. Clin. Cancer Res. 11(2), 664-671 (2005).
129. Kortmansky J, Shah MA, Kaubisch A et al.: Phase I trial of the cyclin-dependent kinase inhibitor and protein kinase C inhibitor Thydroxystaurosporine in combination with fluorouracil in patients with advanced solid tumors. J. Clin. Oncol. 23(9), 1875-1884 (2005).
130. Powis G, Kirkpatrick DL: Thioredoxin signaling as a target for cancer therapy. Curr. Opin. Pharmacol. 7(4), 392-397 (2007).
131. Ramanathan RK, Kirkpatrick DL, Belani CP et al.: A Phase I pharmacokinetic and pharmacodynamic study of PX-12, a novel inhibitor of thioredoxin- 1, in patients with advanced solid tumors. Clin. Cancer Res. 13(7), 2109-2114 (2007).
132. +/ calmodulin antagonist and its anti-proliferative activity against colorectal cancer cells. Biochem. Biophys. Res. Commun. 359(3), 747-751 (2007).
133. McConnell RM, Green AW, Trana CJ et al.: New cathepsin D inhibitors with hydroxyethylamine isosteres: preparation and characterization. Med. Chem. 2(1), 27-38 (2006).
134. Cianchi F, Cortesini C, Magnelli L et al.: Inhibition of 5-lipoxygenase by MK886 augments the antitumor activity of celecoxib in human colon cancer cells. Mol. Cancer Ther. 5(11), 2716-2726 (2006).
135. Rifai N, Gillette MA, Carr SA: Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nat. Biotechnol. 24(8), 971-983 (2006).
136. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM: Reporting recommendations for tumor marker prognostic studies (REMARK). Breast Cancer Res. Treat. 100(2), 229-235 (2006).
137. Hayes DF, Bast RC, Desch CE et al.: Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. J. Natl Cancer Inst. 88(20), 1456-1466 (1996).
138. Hayes DF, Trock B, Harris AL: Assessing the clinical Impact of prognostic factors: when is "statistically significant" clinically useful? Breast Cancer Res. Treat. 52(1-3), 305-319 (1998).
139. Xing X, Lai M, Gartner W etal.: Identification of differentially expressed proteins in colorectal cancer by proteomics: down-regulation of secretagogin. Proteomics 6(9), 2916-2923 (2006).
140. Pei H, Zhu H, Zeng S et al.: Proteome analysis and tissue microarray for profiling protein markers associated with lymph node metastasis in colorectal cancer. J. Proteome Res. 6(7), 2495-2501 (2007).
141. Liu L, Zhao L, Zhang Y, Zhang Q, Ding Y: Proteomic analysis of Tiam1 -mediated metastasis in colorectal cancer. Cell Biol. Int. 31(8), 805-814 (2007).
142. Friedman DB, Hill S, Keller JW et al.: Proteome analysis of human colon cancer by two-dimensional difference get electrophoresis and mass spectrometry. Proteomics 4 (3), 793-811 (2004).
143. Alvarez-Chaver P, Rodriguez-Pineiro, AM, Rodriguez-Berrocal FJ, Martinez-Zorzano VS, Paez DLC: Identification of hydrophobic proteins as biomarker candidates for colorectal cancer. Int. J. Biochem. Cell Biol. 39(3), 529-540 (2007).
144. Yeo M, Kim DK, Park HJ et al.: Loss of transgelin in repeated bouts of ulcerative colitis-induced colon carcinogenesis. Proteomics 6(4), 1158-1165 (2006).
145. Kim H, Kang HJ, You KT et al.: Suppression of human selenium-binding protein 1 is a late event in colorectal carcinogenesis and is associated with poor survival. Proteomics 6(11), 3466-3476 (2006).
146. Tomonaga T, Matsushita K, Yamaguchi S et al.: Identification of altered protein expression and post-translational modifications in primary colorectal cancer by using agarose two-dimensional gel electrophoresis. Clin. Cancer Res. 10 (6), 2007-2014 (2004).
147. Alfonso P, Nunez A, Madoz-Gurpide J, Lombardia L, Sanchez L, Casal JI: Proteomic expression analysis of colorectal cancer by two-dimensional differential gel electrophoresis. Proteomics 5(10), 2602-2611 (2005).
148. Dall'Agnol M, Bernstein C, Bernstein H, Garewal H, Payne CM: Identification of S-nitrosylated proteins after chronic exposure of colon epithelial cells to deoxycholate. Peoteomics 6(5), 1654-1662 (2006).
149. Yu B, Li SY, An P et al.: Comparative study of proteome between primary cancer and hepatic metastatic tumor in colorectal cancer. World J. Gastroenterol. 10(18), 2652-2656 (2004).
150. Balasubramani M, Day BW, Schoen RE, Getzenberg RH: Altered expression and localization of creatine kinase B, heterogeneous nuclear ribonucleoprotein F, and high mobility group box 1 protein in the nuclear matrix associated with colon cancer. Cancer Res. 66(2), 763-769 (2006).
151. Brunagel G, Vietmeier BN, Bauer AJ, Schoen RE, Getzenberg RH: Identification of nuclear matrix protein alterations associated with human colon cancer. Cancer Res. 62(8), 2437-2442 (2002).
152. Brunagel G, Schoen RE, Bauer AJ, Vietmeier BN, Getzenberg RH: Nuclear matrix protein alterations associated with colon cancer metastasis to the liver. Clin. Cancer Res. 8(10), 3039-3045 (2002).
153. Juan HF, Chen JH, Hsu WT et al.: Identification of tumor-associated plasma biomarkers using proteomic techniques: from mouse to human. Proteomics 4(9), 2766-2775 (2004).
154. Melle C, Bogumil R, Ernst G, Schimmel B, Bleul A, Von Eggeling F: Detection and identification of heat shock protein 10 as a biomarker in colorectal cancer by protein profiling. Proteomics 6(8), 2600-2608 (2006).
155. Brunagel G, Schoen RE, Getzenberg RH: Colon cancer specific nuclear matrix protein alterations in human colonic adenomatous polyps. J. Cell Biochem. 91(2), 365-374 (2004).
156. Chaurand P, DaGue BB, Pearsall RS, Threadgill DW, Caprioli RM: Profiling proteins from azoxymethane-induced colon tumors at the molecular level by matrix-assisted laser desorption/ionization mass spectrometry. Proteomics 1(10), 1320-1326 (2001).
157. Melle C, Ernst G, Schimmel B et al.: Different expression of calgizzarin (S100A11) in normal colonic epithelium, adenoma and colorectal carcinoma. Int. J. Oncol. 28(1), 195-200 (2006).
158. Stulik J, Osterreicher J, Koupilova K et al.: The analysis of S100A9 and S100A8 expression in matched sets of macroscopically normal colon mucosa and colorectal carcinoma: the S100A9 and S100A8-positive cells underlie and invade tumor mass. Electrophoresis 20(4-5), 1047-1054 (1999).
159. Stulik J, Kovarova H, Macela A et al.: Overexpression of calcium-binding protein calgranulin B in colonic mucosal diseases. Clin. Chim. Acta 265(1), 41-55 (1997).
160. Chen WS, Chang HY, Li CP, Liu JM, Huang TS: Tumor β-1,4-galactosyltransferase IV overexpression is closely associated with colorectal cancer metastasis and poor prognosis. Clin. Cancer Res. 11(24), 8615-8622 (2005).
161. Knosel T, Emde A, Schluns K et al.: Immunoprofiles of 11 biomarkers using tissue microarrays identify prognostic subgroups in colorectal cancer. Neoplasia 7(8), 741-747 (2005).
162. Emoto K, Yamada Y, Sawada H et al.: Annexin II overexpression correlates with stromal tenascin-C overexpression: a prognostic marker in colorectal carcinoma. Cancer 92(6), 1419-1426 (2001).
163. Bekku S, Mochizuki H, Yamamoto T, Ueno H, Takayama E, Tadakuma T: Expression of carbonic anhydrase I or II and correlation to clinical aspects of colorectal cancer. Hepatogastroenterology 47(34), 998-1001 (2000).
164. Cappello F, David S, Rappa F et al.: The expression of HSP60 and HSP10 in large bowel carcinomas with lymph node metastase. BMC Cancer 5, 139 (2005).
165. Lazaris AC, Theodoropoulos GE, Davaris PS et al.: Heat shock protein 70 and HLA-DR molecules tissue expression. Prognostic implications in colorectal cancer. Dis. Colon Rectum 38(7), 739-745 (1995).
166. Yamazaki T, Kanda T, Sakai Y, Hatakeyama K: Liver fatty acid-binding protein is a new prognostic factor for hepatic resection of colorectal cancer metastases. J. Surg. Oncol. 72(2), 83-87 (1999).
167. Lyall MS, Dundas SR, Curran S, Murray GI: Profiling markers of prognosis in colorectal cancer. Clin. Cancer Res. 12(4), 1184-1191 (2006).
168. Raffel J, Bhattacharyya AK, Gallegos A et al.: Increased expression of thioredoxin-1 in human colorectal cancer is associated with decreased patient survival. J. Lab. Clin. Med. 142(1), 46-51 (2003).
169. Ngan CY, Yamamoto H, Seshimo I et al.: Quantitative evaluation of vimentin expression in tumor stroma of colorectal cancer. Br. J. Cancer 96(6), 986-992 (2007).